España
India
Italia
대한민국
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
ResMed
RMD
NYSE
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$236.18
-21.47
-8.33%
At close: -
$236.18
0.00
0.00%
After Hours: Jan 31, 4:07 PM EDT
Get Report
Comment
Q2 2025 Earnings were released on Thu Jan 30th, after the market close
The most recent conference call was at 16:30 PM, 2 days ago
Click to view past webcast
ResMed (RMD) Forecast
News
Earnings
ResMed (RMD) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Government Trades
Short Interest
Latest news for ResMed (NYSE:RMD) Stock
ResMed Stock (NYSE: RMD)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, January 31, 2025
JP Morgan Maintains Overweight on ResMed, Rai...
Benzinga Newsdesk
Tech Stocks Rally, S&P 500 Flirts With Records, Gold Extends All-Time Highs: What's Driving Markets Friday?
Piero Cingari
ResMed shares are trading lower. The company ...
Benzinga Newsdesk
Keybanc Maintains Overweight on ResMed, Raise...
Benzinga Newsdesk
Piper Sandler Maintains Neutral on ResMed, Ra...
Benzinga Newsdesk
Needham Reiterates Hold on ResMedto Hold
Benzinga Newsdesk
Thursday, January 30, 2025
Earnings Breakdown: ResMed Q2
Benzinga Insights
ResMed Earnings Analysis: Q2 Recap
Benzinga Insights
ResMed Q2 2025 Adj EPS $2.43 Beats $2.32 Esti...
Benzinga Newsdesk
Wall Street Remains Flat, Microsoft Eyes Heaviest Drop Since Late 2022, Gold Sets Fresh Records: What's Driving Markets Thursday?
Piero Cingari
Earnings Scheduled For January 30, 2025
Benzinga Insights
Friday, January 10, 2025
This AppLovin Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Avi Kapoor
What 5 Analyst Ratings Have To Say About ResMed
Benzinga Insights
Piper Sandler Initiates Coverage On ResMed wi...
Benzinga Newsdesk
Monday, December 23, 2024
ResMed shares are trading lower after rival E...
Benzinga Newsdesk
Friday, December 13, 2024
This AutoZone Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Avi Kapoor
Stifel Initiates Coverage On ResMed with Hold...
Benzinga Newsdesk
Thursday, November 28, 2024
Insider Transaction: Michael J Farrell Sells $499K Worth Of ResMed Shares
Benzinga Insights
Insider Activity Spotlight: Michael J Farrell Acquires In ResMed Stock Options
Benzinga Insights
Wednesday, November 27, 2024
Peter C Farrell Decides To Exercise Options At ResMed
Benzinga Insights
Monday, October 28, 2024
P/E Ratio Insights for ResMed
Benzinga Insights
Friday, October 25, 2024
RBC Capital Maintains Sector Perform on ResMe...
Benzinga Newsdesk
Tech Stocks Rally As Investors Await Magnificent 7 Earnings; Dollar Eyes Fourth Straight Positive Week: What's Driving Markets Friday?
Piero Cingari
Keybanc Maintains Overweight on ResMed, Raise...
Benzinga Newsdesk
Sleep Apnea Device Maker ResMed Is A Durable MedTech, With Positive Fundamentals, Says Analyst
Vandana Singh
Cracking The Code: Understanding Analyst Reviews For ResMed
Benzinga Insights
Baird Maintains Outperform on ResMed, Raises ...
Benzinga Newsdesk
ResMed shares are trading higher after the co...
Benzinga Newsdesk
CORRECTION: ResMed Ticker Is RMD
Benzinga Newsdesk
Needham Reiterates Hold on ResMed
Benzinga Newsdesk
Thursday, October 24, 2024
ResMed shares are trading higher after the co...
Benzinga Newsdesk
ResMed Q1 2025 Adj. EPS $2.20 Beats $2.04 Est...
Benzinga Newsdesk
Wednesday, October 23, 2024
A Peek at ResMed's Future Earnings
Benzinga Insights
Tuesday, October 01, 2024
RBC Capital Maintains Sector Perform on ResMe...
Benzinga Newsdesk
Needham Reiterates Hold on ResMed
Benzinga Newsdesk
Monday, September 30, 2024
ResMed Unveils 2030 Strategy To Drive Growth,...
Benzinga Newsdesk
ResMed Enhances CPAP Therapy With Its First F...
Benzinga Newsdesk
Thursday, September 26, 2024
B of A Securities Maintains Buy on ResMed, Ra...
Benzinga Newsdesk
Tuesday, September 24, 2024
Expert Outlook: ResMed Through The Eyes Of 7 Analysts
Benzinga Insights
Baird Initiates Coverage On ResMed with Outpe...
Benzinga Newsdesk
Wednesday, September 18, 2024
Stocks Edge Lower As Fed Rate Decision Looms, Treasury Yields Rise As Odds Improve For Smaller Cut: What's Driving Markets Wednesday?
Piero Cingari
ResMed shares are trading lower after Wolfe R...
Benzinga Newsdesk
Needham Reiterates Hold on ResMed
Benzinga Newsdesk
Wolfe Research Downgrades ResMed to Underperf...
Benzinga Newsdesk
Wednesday, September 11, 2024
Reasons to Retain ResMed Stock in Your Portfolio for Now
Zacks
Monday, September 09, 2024
Here's How Much You Would Have Made Owning ResMed Stock In The Last 15 Years
Benzinga Insights
ResMed shares are trading higher. The stock s...
Benzinga Newsdesk
Apple Announces New Sleep Apnea Features On A...
Benzinga Newsdesk
Wednesday, September 04, 2024
A Glimpse Into The Expert Outlook On ResMed Through 6 Analysts
Benzinga Insights
Needham Downgrades ResMed to Hold, Maintains ...
Benzinga Newsdesk
Show More